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Objectives: To evaluate associations of
preoperative total prostate specific antigen
(PSA) to free testosterone (FT), the PSA/FT index ratio, with
features of pathology prostate cancer (PCA) and to investi-
gate its prognostic potential in clustering the PCA population. 
Patients and methods: After excluding criteria, the records of
220 patients who underwent radical prostatectomy (RP) were
retrospectively reviewed. Serum samples of PSA, total testos-
terone (TT) and FT were collected at 8.00 A.M., one month
after biopsies and before RP. The PSA/FT ratio was computed
in the population of patients who were clustered in groups
according to ranking intervals of the PSA/FT ratio which
identified at least 4 clusters which were coded as A, B, C, and
D. The independent associations of the PSA/FT index ratio
were assessed by statistical methods and a two-sided P < 0.05
was considered to indicate statistical significance.
Results: TT correlated to FT which was a significant predic-
tor of PSA in the population of patients who were subse-
quently clustered, according to increasing interval values of
the PSA/FT index ratio, in groups that showed a stronger lin-
ear association of FT with PSA. The PSA/FT index ratio sig-
nificantly associated with pathology features of prostate can-
cer such as pathology Gleason score (pGS), invasion of the
seminal vesicles (pT3b), proportion of positive cores (P+) and
proportion of cancer involving the volume of the prostate. In
the population of patients, TT, PSA/FT index ratio and P+
independently associated with pGS ≥ 7 and pT3b; moreover,
the odds ratio (OR) of the PSA/FT index ratio resulted 9.11
which was stronger than TT (OR = 1.11) and P+ (OR = 8.84).
In the PCA population, TT, PSA/FT index ratio and P+ also
independently associated with pT3b PCA; interestingly, the
OR of PSA/FT index resulted 54.91 which was stronger than
TT (OR = 1.31) and P+ (26.43).     
Conclusions: Preoperative PSA/FT index ratio is an independ-
ent strong factor which directly associates with aggressive
features of pathology PCA; moreover, it might express prog-
nostic potential for clustering the patient population in risk
classes. Confirmatory studies are required.  
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INTRODUCTION
The biology of the prostate gland is closely related to the
endocrine system which includes the hypothalamus, the
pituitary, the adrenals and the testes. The interstitial cells
of Leydig of the testes are responsible for the production
of 95% of all circulating androgens in the form of total
testosterone (TT). Approximately 98% of the circulating
androgens are bound to plasma proteins, including a
specific beta-globulin, testosterone-binding globulin
(TeBG). The free testosterone (FT) in the blood is the
physiologically important fraction. 
It has been shown that prostate cancer (PCA) is an
endocrine tumor which is androgen dependent (1) and
associates with increased PSA serum levels (2, 3). Since
the pioneering work of Charles Huggins (1), androgens
have been universally considered as being pivotal in the
regulation of normal function and malignant growth of the
prostate; moreover, pretreatment TT serum levels have
been detected abnormal in the PCA population (4-7). 
Actually, according to updated statistics, PCA, in the USA
as in Europe, is, after lung cancer, the second most fre-
quent solid tumor in adult males (8). Moreover, it has
been estimated a cumulative risk of 3.9% and a mortali-
ty rate of 1.2% for PCA (9). The stratification of PCA
patients in clinical class risk (CCR) groups is important
for planning treatments of low (L), intermediate (I) and
high (H) PCA CCR (10). The inclusion of PCA patients
in CCR classes involves the computation of total prostate
specific antigen (PSA), biopsy Gleason score (bGS) and
clinical staging (cT). However, although being an
endocrine dependent tumor, PCA is generally staged
without investigating on hormonal features. As a result,
the CCR of PCA patients do not include endocrine fea-
tures which may relate to tumour biology. 
The primary aim of the study was to evaluate independ-
ent associations of preoperative total PSA to FT ratio, the
PSA/FT index ratio, with features of pathology PCA. The
secondary endpoint of the trial was to investigate the
prognostic potential of the PSA/FT index ratio for clus-
tering the PCA population into risk classes. 
DOI: 10.4081/aiua.2016.1.17
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PATIENTS AND METHODS
The present study, carried out from 2007 to 2011, was
part of a larger trial which aimed at evaluating a potential
link between PCA and the hypothalamus - pituitary - testis
- prostate axis. The investigation included only patients
who had not previously received 5α-reductase inhibitors,
LH-releasing hormone analogues or testosterone replace-
ment treatment. The trial was retrospective and included
patients who underwent standard retropubic prostatecto-
my (RRP) which was eventually associated with local
lymph node dissection (LND). The diagnosis of PCA was
performed by the 14-core Trans Rectal Ultrasound Scan
(TRUS) guided prostate biopsy technique which also
included additional cores of lesions detected by either
TRUS and/or digital rectal examination (DRE). The biopsy
Gleason score (bGS) of positive cores was assessed by an
experienced pathologist. The percentage of positive cores
(P+) detected by TRUS was computed after diagnosis of
PCA. The prostatectomy specimens were fixed in toto
overnight (10% neutral buffered formhaldeyde), coated
with India ink and then weighted (Wi). Tissue sections of
4 µm were prepared in standard fashion and stained with
hematoxylin and eosin. Patients were classified according
to primary tumor stage, lymph node and metastatic status,
using the TNM categories. Patients were then classified
according to the D’Amico CCR groups (10). Tumors
invading and extending beyond the capsule were coded as
pT3a. Invasion of the bladder neck without involvement
of the seminal vesicles was also staged as pT3a. Seminal
vesicle invasion was defined as tumor involving of the
muscular wall and was coded as pT3b. Surgical margins
(SM) were stated as free (N) or involved by cancer (P).
Tumors were graded according to the Gleason grading sys-
tem and the pathology Gleason score (pGS) was comput-
ed after summing up the two pathology Gleason patterns
(pGP), prevalent (pGP-I) and secondary (pGP-II). Also,
overall proportion of cancer involving prostate volume
was estimated coded as V+. 
A detailed informed signed consent was obtained by the
patients who were preoperatively assessed for simultane-
ous serum levels of TT, FT and total PSA. 
The samples were collected at least one month after
prostate biopsies at 8.00 ante meridian and analyzed at
our laboratory. TT (normal range: 9-29 nmol/l) and PSA
(normal range: 2-4 ug/l) were measured by immuno-
chemiluminescent test performed by ADVIA Centaur XP
Immunoassay System (Siemens Company). FT (normal
range: 31-163 pmol/l) was measured by immunoradio-
metric test (DSL, USA).  The population was clustered by
sequencing into intervals the range of the PSA/FT index
ratio which was obtained by dividing total PSA by FT
(PSA/FT index ratio) in each patient. The PSA/FT index
ratio ranged between 0.04 to 1.48. 
According to the interval values of the PSA/FT index
ratio, patients were clustered in the following 3 patterns:
(i) AB (0.04 ≤ PSA/FT ≤ 0.18) and CD (0.18 < PSA/FT ≤
1.48); (ii) A (0.04 ≤ PSA/FT ≤ 0.13), B (0.13 < PSA/FT ≤
0.18), C (0.18 < PSA/FT ≤ 0.27) and D (0.27 < PSA/FT
≤ 1.48); (iii) A1 (0.04 ≤ PSA/FT ≤ 0.10), A2 (0.10 <
PSA/FT ≤ 0.13), B (0.13 < PSA/FT ≤ 0.18), C (0.18 <
PSA/FT ≤ 0.27), D1 (0.27 < PSA/FT ≤ 0.43) and D2
(0.43 < PSA/FT ≤ 1.48). 
STATISTICAL METHODS
It was computed the summary statistics of the patient
population of patients who were stratified according to
CCR groups in which differences were assessed by the
Kruskal-Wallis test (continuous variables) and by the Chi
Squared test (categorical variables). The association of FT
with PSA was assessed by simple linear regression analy-
sis in either the population and subpopulations of
patients who were clustered according to the PSA/FT
index ratio. The differences between groups of the pop-
ulation of patients who were clustered according to the
PSA/FT index ratio were assessed by the Chi Squared
and Kruskal-Wallis statistic tests. The association of the
variables, including also the PSA/FT index ratio, with
aggressive PCA (pGS ≥ 7 or pT3b) was assessed by logis-
tic regression which also included the analysis of multi-
ple independent clinical models predicting aggressive
PCA biology. A two-sided P < 0.05 was considered to
indicate statistical significance.
RESULTS
The analysis included 220 patients whose summary sta-
tistics has already been reported elsewhere (11, 12).
Table 1 shows the comparing statistics of the 220 oper-
ated patients who were stratified according to CCR
groups (10). As shown, the CCR groups were signifi-
cantly different for many of the investigated variables. TT
and FT did not show any difference among the CCR
groups of patients who however had different values of
the PSA/FT index ratio (P < 0.0001). 
In the population of patients, TT correlated to FT which
significantly associated with PSA (Supplementary Materials
Fi gu re 1). Table 2 shows the results of simple linear regres-
sion analysis of FT predicting PSA which was always sig-
nificant in the population, clusters (AB/CD, A/B/C/D) and
subclusters (A1/A2 and D1/D2) of patients who were
grouped according to the PSA/FT index ratio. Interestingly,
the coefficient of determination (R2) progressively
increased along the PSA/FT index ratio by which the pop-
ulation was clustered (Table 2) (Supple men tary Materials
Figures 2-4). 
As shown in Table 3, the PSA/FT index not only associ-
ated with CCR, high grade (pGS > 7, pGS-I > 3) and high
stage (pT3b) PCA, but also contributed in assessing more
risk clusters inside each group of CCR (L, I, H), pGS
(6, 7, > 7) and pT (2, 3a, 3b). In particular, a low PSA/FT
index ratio associated with less aggressive PCA (low
CCR, grade and stage PCA), while a high PSA/FT index
ratio progressively associated with more aggressive and
extensive disease (high CCR, high grade and high stage
disease). The PSA/FT index ratio directly and significant-
ly associated with P+ and V+ (biology aggressive PCA)
(Supple mentary Materials Tables 4a, 4b, 4c). Moreover,
as expected, the PSA/FT index ratio directly associated
with total PSA and inversely with TT. There was no asso-
ciation of the PSA/FT index ratio with age and WGT of
the prostate.
The PSA/FT index ratio was a significant and strong inde-
pendent predictor which directly associated with pGS ≥ 7
(Supplementary Materials Table 5). Interestingly, the PSA/FT
index ratio was the strongest independent predictive variable
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which directly associated with pGS ≥ 7; indeed, for every
increase of one-unit in the PSA/FT index ratio, the risk of pGS
≥ 7 increased 9.11 times (Supplementary Materials Table 6
model b6). TT, PSA, P+, V+ and PSA/FT associated with pT3b
PCA in simple models (Supplementary Materials Table 6 section
a1-a8). 
In multivariate models, the PSA/FT index ratio was a signifi-
cant and independent predictor of pT3b PCA. Interestingly,
the PSA/FT index ratio was the strongest independent variable
when predicting pT3b disease (Supplementary Materials Table
6 model b7); indeed, the association indicated that for every
increase in one unit of the PSA/FT index ratio, the risk of pT3b
increased 54.914 times.   
DISCUSSION
In the present study, we have shown that FT significant-
ly associated with PSA in the population of patients.
Since the prediction of FT on PSA was linear, we conse-
quently clustered the population of patients according to
the PSA/FT index ratio which geometrically represents
the variation of the gradient of the regression line associ-
ating FT with PSA (Table 2) (Supplementary Ma terials
Figures 1-4). The PSA/FT index ratio independently asso-
ciated with biologically aggressive prostate cancer
(Supplementary Materials Tables 5-6); moreover, the asso-
ciation was strong since the OR was 9.11 when the
PSA/FT ratio predicted pGS ≥ 7 and 54.91 when it pre-
Table 1. 
Statistics of the
patient population
stratified according
to the D'Amico's
class risk.
Legend: 
CCR, cancer class risk; 
L, low class risk; 
I, intermediate class risk;
H, high class risk.  
Porcaro_Stesura Seveso  08/04/16  11:26  Pagina 19
Archivio Italiano di Urologia e Andrologia 2016; 88, 1
A.B. Porcaro, B. Caruso, A. Terrin, N. De Luyk, G. Cacciamani, P. Corsi, D. Inverardi, D. De Marchi, R. Baldassarre, M. Cerruto, et al.
20
Table 3. 
Statistics of the categorical variables of the patient population (n = 200) stratified according to the PSA/FT index ratio.
in different clusters.
Legend: B, coefficient; SDE, standard deviation error; bo, constant; FT, FT predictor; R², coefficient of determination.
Table 2. 
Simple linear
regression models
in the population
and subpopulation
of patients
according 
to the PSA/FT
index ratio. 
Legend: 
B, coefficient; 
SDE, standard deviation error; 
bo, constant; 
FT, FT predictor; 
R², coefficient of determination.
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dicted pT3b. The measure of the association with PCA is
interesting; indeed, when the PSA/FT index ratio pre-
dicted pGS ≥ 7, the OR indicated that for every increase
of one-unit in the PSA/FT index ratio, the risk of pGS ≥
7 increased 9.11 times; moreover, when it independent-
ly predicted pT3b, the OR indicated that for every
increase in one unit of the PSA/FT index ratio, the risk of
pT3b increased 54.91 times. Because of the strong asso-
ciation with either pGS ≥ 7. and pT3b, the PSA/FT index
ratio was effective for grouping preoperatively the patient
population in sub clusters according to rising the values
of the of the index variable. Interestingly, rising values of
the PSA/FT ratio directly associated with PCA biology
expressed by tumor grade and stage. The strong associa-
tion of the PSA/FT index ratio with PCA biology might
be related to PCA physiopathology along the hypothala-
mic-pituitary-testis prostate axis in which FT, since being
the biologically active androgen, stimulates either nor-
mal and cancerous cells which both produce PSA which
not only relates to prostate volume but also to PCA. As a
result, the PSA/FT index ratio is a parameter functional-
ity related to PCA biology and this might also explain
why, in multivariate logistic models (Supplementary
Materials Tables 5-6), the independent prediction of
PSA/FT was stronger than PSA in either pGS ≥ 7 (OR:
9.11 versus 1.05) and pT3b (OR: 54.91 versus 1.13). As
a theory, the PSA/FT index ratio is a potential prognostic
factor because it associates functionally with biology and
natural history of PCA (13-16). The present larger study
confirms our preliminary investigations which showed
that PCA biology relates to either PSA and FT serum lev-
els; moreover, the PSA/FT ratio is as a growing rate
parameter which expresses cancer phenotype biology
(17-19). Indeed, the production of PSA in most tumors
is initially androgen regulated and undergoes a sharp
decline following medical or surgical castration (20).
The stratification of PCA patients in CCR groups (L, I, H)
is important for prognosis and treatment (3). 
However, L -I CCR groups are not homo genous be cause of
the limits related to clinical staging procedures; as a result,
high risk PCA is missed. Indeed, low risk PCA may be
treated by active surveillance (AS) which offers low cancer
specific mortality (21); however, about a third of these
cases will progress requiring definitive treatment (21-22).
The present investigation showed that the PSA/FT index
ratio was a strong independent predictive factor associated
with aggressive PCA. 
Interestingly, in either L and I CCR, the PSA/FT index ratio
identified different clusters (A, B, C, D) and sub clusters
(A1, A2, D1, D2). Clusters C and D associated with aggres-
sive PCA which was missed by clinical staging procedures.
In H CCR PCA, it was not detected any low risk cluster (A,
B) but only high risk ones (C, D). 
In our opinion, the PSA/FT index ratio selects PCA patients
in prognostic groups because it represents the specific
growing rate parameter which is expression of the biology
of the tumor (17-19). 
The measures of TT and FT serum levels in L-CCR of
patients who undergo AS might express prognostic
potential. Indeed, it has been shown that, in AS patients,
the risk of progression associates with low FT serum lev-
els (23). The present study showed that the PSA/FT
index ratio identified clusters (A, B, C, D) in which the
mean values of TT and FT were decreasing significantly
(Supplementary Materials Table 4); as a result, lower mean
levels of androgens were detected in aggressive PCA.     
The results of our study might have theoretical draw-
backs of PCA molecular biology. Indeed, the PSA/FT
index ratio associated with pGS > 7 (Table 3) of which a
high rate was detected in subclusters A1 (17%), C
(26.1%) and D2 (34%); moreover, mean PSA values were
detected lower in subclusters A1 and C, which showed
different mean values of FT (higher in the former and
lower in the latter), but increasingly higher in D1-D2
which both had lower mean values of FT (Sup ple mentary
Materials Table 4). 
As a consequence, we speculate that high grade tumors in
A, B clusters have a phenotype which is less aggressive than
that in C-D subgroups. However, the hypothesis need to be
verified by studies investigating PCA molecular biology.   
There are limits in our study which was retrospective,
included a small number of cases, did not relate molec-
ular biology to the grade of tumours and lacks of confir-
matory studies. Finally, it does not include follow-up
which however is still ongoing and will be the subject of
further analysis. However, in our opinion, this is the first
study that shows, in PCA cases, a functional relationship
between PSA and FT which is expressed by the PSA/FT
ratio which directly associates with PCA biology.   
CONCLUSIONS
Our study shows that the preoperative PSA/FT index ratio
is a strong independent factor which directly associates
with aggressive PCA features; moreover, it might have
prognostic potential for clustering the patient population
into risk classes. Confirmatory studies are required. 
Tables 4-6 and Figures 1-4 are posted on www.aiua.it
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